ArticleDrug safety2020

Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment.

Vicki Osborne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.